These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32601817)

  • 21. Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF.
    Pilotto E; Frizziero L; Daniele AR; Convento E; Longhin E; Guidolin F; Parrozzani R; Cavarzeran F; Midena E
    Br J Ophthalmol; 2019 Jan; 103(1):67-71. PubMed ID: 29567794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy.
    Sahoo NK; Mishra SB; Iovino C; Singh SR; Munk MR; Berger L; Peiretti E; Chhablani J
    Br J Ophthalmol; 2019 Nov; 103(11):1615-1618. PubMed ID: 30602447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term Progression of Type 1 Neovascularization in Age-related Macular Degeneration Using Optical Coherence Tomography Angiography.
    Xu D; Dávila JP; Rahimi M; Rebhun CB; Alibhai AY; Waheed NK; Sarraf D
    Am J Ophthalmol; 2018 Mar; 187():10-20. PubMed ID: 29269100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol.
    Adrean SD; Chaili S; Grant S; Pirouz A
    Ophthalmol Retina; 2018 Mar; 2(3):225-230. PubMed ID: 31047590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.
    Romdhane K; Zola M; Matet A; Daruich A; Elalouf M; Behar-Cohen F; Mantel I
    Br J Ophthalmol; 2020 Jul; 104(7):910-916. PubMed ID: 31615761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fundus autofluorescence not predictive of treatment response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Chhablani J; Kozak IR; Mojana F; Cheng L; Morrison VL; Wang H; Kim JS; Dustin L; Azen S; Freeman WR
    Retina; 2012 Sep; 32(8):1465-70. PubMed ID: 22466489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
    Roller AB; Amaro MH
    Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
    Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
    Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Exudative Activity of Choroidal Neovascularization in Age-Related Macular Degeneration by OCT Angiography.
    von der Emde L; Thiele S; Pfau M; Nadal J; Meyer J; Möller PT; Schmid M; Fleckenstein M; Holz FG; Schmitz-Valckenberg S
    Ophthalmologica; 2020; 243(2):120-128. PubMed ID: 31665719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonexudative morphologic changes of neovascularization on optical coherence tomography angiography as predictive factors for exudative recurrence in age-related macular degeneration.
    Cho HJ; Kim J; Nah SK; Lee J; Kim CG; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):839-848. PubMed ID: 34515840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LONGITUDINAL OPTICAL COHERENCE TOMOGRAPHY-ANGIOGRAPHY STUDY OF TYPE 2 NAIVE CHOROIDAL NEOVASCULARIZATION EARLY RESPONSE AFTER TREATMENT.
    Lumbroso B; Rispoli M; Savastano MC
    Retina; 2015 Nov; 35(11):2242-51. PubMed ID: 26457401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Cheng Y; Li Y; Huang X; Qu Y
    Retina; 2019 Apr; 39(4):712-718. PubMed ID: 29256987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treat-and-extend approach with aflibercept: Effects on different subtypes of age-related choroidal neovascularisation.
    Castro-Navarro V; Cervera-Taulet E; Montero-Hernández J; Navarro-Palop C
    Arch Soc Esp Oftalmol; 2017 Mar; 92(3):112-119. PubMed ID: 27816486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of Nonexudative Choroidal Neovascularization and Progression to Exudative Choroidal Neovascularization Using OCT Angiography.
    Bailey ST; Thaware O; Wang J; Hagag AM; Zhang X; Flaxel CJ; Lauer AK; Hwang TS; Lin P; Huang D; Jia Y
    Ophthalmol Retina; 2019 Aug; 3(8):629-636. PubMed ID: 31068262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D; Sarao V; Lanzetta P
    J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.